{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T16:42:15Z","timestamp":1786984935339,"version":"build-2736575974"},"reference-count":86,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,6,9]],"date-time":"2021-06-09T00:00:00Z","timestamp":1623196800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100010661","name":"Horizon 2020 Framework Programme","doi-asserted-by":"publisher","award":["779316"],"award-info":[{"award-number":["779316"]}],"id":[{"id":"10.13039\/100010661","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003130","name":"FWO","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003130","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Autoimmunity Reviews"],"published-print":{"date-parts":[[2021,8]]},"DOI":"10.1016\/j.autrev.2021.102873","type":"journal-article","created":{"date-parts":[[2021,6,11]],"date-time":"2021-06-11T02:13:42Z","timestamp":1623377622000},"page":"102873","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Safety and immunological proof-of-concept following treatment with tolerance-inducing cell products in patients with autoimmune diseases or receiving organ transplantation: A systematic review and meta-analysis of clinical trials"],"prefix":"10.1016","volume":"20","author":[{"given":"Barbara","family":"Willekens","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inez","family":"Wens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristien","family":"Wouters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Cras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathalie","family":"Cools","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.autrev.2021.102873_bb0005","doi-asserted-by":"crossref","first-page":"471719","DOI":"10.1155\/2015\/471719","article-title":"Clinical use of Tolerogenic dendritic cells-harmonization approach in European collaborative effort","volume":"2015","author":"Ten Brinke","year":"2015","journal-title":"Mediat. Inflamm."},{"key":"10.1016\/j.autrev.2021.102873_bb0010","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1007\/s40259-017-0228-3","article-title":"Cell-based therapies with T regulatory cells","volume":"31","author":"Gliwinski","year":"2017","journal-title":"BioDrugs"},{"key":"10.1016\/j.autrev.2021.102873_bb0015","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1038\/s41577-019-0232-6","article-title":"T-reg cell-based therapies: challenges and perspectives","volume":"20","author":"Raffin","year":"2020","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.autrev.2021.102873_bb0020","doi-asserted-by":"crossref","first-page":"579","DOI":"10.2174\/1574888X14666190429141421","article-title":"Current research and use of mesenchymal stem cells in the therapy of autoimmune diseases","volume":"14","author":"Chen","year":"2019","journal-title":"Curr Stem Cell Res Ther"},{"key":"10.1016\/j.autrev.2021.102873_bb0025","doi-asserted-by":"crossref","first-page":"2228","DOI":"10.1172\/JCI78088","article-title":"Mechanisms of human autoimmunity","volume":"125","author":"Rosenblum","year":"2015","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.autrev.2021.102873_bb0030","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/j.semarthrit.2018.09.008","article-title":"Therapeutic tolerance in autoimmune disease","volume":"48","author":"Rayner","year":"2018","journal-title":"Semin. Arthritis Rheum."},{"key":"10.1016\/j.autrev.2021.102873_bb0035","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/978-1-4939-8938-6_12","article-title":"Immune tolerance and rejection in organ transplantation","volume":"1899","author":"Stolp","year":"2019","journal-title":"Methods in molecular biology (Clifton, NJ)"},{"key":"10.1016\/j.autrev.2021.102873_bb0040","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/j.anclin.2017.04.001","article-title":"Overview of immunosuppressive therapy in solid organ transplantation","volume":"35","author":"Holt","year":"2017","journal-title":"Anesthesiol. Clin."},{"key":"10.1016\/j.autrev.2021.102873_bb0045","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1097\/01.JAA.0000694948.01963.f4","article-title":"Infectious disease considerations in immunocompromised patients","volume":"33","author":"McGrath","year":"2020","journal-title":"JAAPA"},{"key":"10.1016\/j.autrev.2021.102873_bb0050","article-title":"Prospects of the use of cell therapy to induce immune tolerance","volume":"11","author":"Wang","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.autrev.2021.102873_bb0055","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1016\/S0952-7915(98)80217-3","article-title":"Infectious tolerance","volume":"10","author":"Cobbold","year":"1998","journal-title":"Curr. Opin. Immunol."},{"key":"10.1016\/j.autrev.2021.102873_bb0060","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1038\/80516","article-title":"Encephalitogenic potential of the myelin basic protein peptide (amino acids 83-99) in multiple sclerosis: results of a phase II clinical trial with an altered peptide ligand","volume":"6","author":"Bielekova","year":"2000","journal-title":"Nat. Med."},{"key":"10.1016\/j.autrev.2021.102873_bb0065","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.664244","article-title":"Immune monitoring for advanced cell therapy trials in transplantation: which assays and when?","volume":"12","author":"Stark","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.autrev.2021.102873_bb0070","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.3389\/fimmu.2017.01870","article-title":"Monitoring T-cell responses in translational studies: optimization of dye-based proliferation assay for evaluation of antigen-specific responses","volume":"8","author":"Ten Brinke","year":"2017","journal-title":"Front. Immunol."},{"key":"10.1016\/j.autrev.2021.102873_bb0075","article-title":"ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions","volume":"355","author":"Sterne","year":"2016","journal-title":"BMJ (Clinical research ed)"},{"key":"10.1016\/j.autrev.2021.102873_bb0080","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ (Clinical research ed)"},{"key":"10.1016\/j.autrev.2021.102873_bb0085","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1002\/jrsm.1411","article-title":"Risk-of-bias VISualization (robvis): An R package and Shiny web app for visualizing risk-of-bias assessments","volume":"12","author":"McGuinness","year":"2021","journal-title":"Res. Synth. Methods"},{"key":"10.1016\/j.autrev.2021.102873_bb0090","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1000100","article-title":"The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration","volume":"6","author":"Liberati","year":"2009","journal-title":"PLoS Med."},{"key":"10.1016\/j.autrev.2021.102873_bb0095","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1186\/s13063-019-3346-z","article-title":"MEsenchymal StEm cells for Multiple Sclerosis (MESEMS): a randomized, double blind, cross-over phase I\/II clinical trial with autologous mesenchymal stem cells for the therapy of multiple sclerosis","volume":"20","author":"Uccelli","year":"2019","journal-title":"Trials"},{"key":"10.1016\/j.autrev.2021.102873_bb0100","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaa9301","article-title":"Citrullinated peptide dendritic cell immunotherapy in HLA risk genotype-positive rheumatoid arthritis patients","volume":"7","author":"Benham","year":"2015","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.autrev.2021.102873_bb0105","doi-asserted-by":"crossref","first-page":"2026","DOI":"10.2337\/dc11-0472","article-title":"Phase I (safety) study of autologous tolerogenic dendritic cells in type 1 diabetic patients","volume":"34","author":"Giannoukakis","year":"2011","journal-title":"Diabetes Care"},{"key":"10.1016\/j.autrev.2021.102873_bb0110","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1507\/endocrj.EJ12-0343","article-title":"Long term effects of the implantation of Wharton\u2019s jelly-derived mesenchymal stem cells from the umbilical cord for newly-onset type 1 diabetes mellitus","volume":"60","author":"Hu","year":"2013","journal-title":"Endocr. J."},{"key":"10.1016\/j.autrev.2021.102873_bb0115","doi-asserted-by":"crossref","first-page":"587","DOI":"10.2337\/db14-0656","article-title":"Preserved beta-cell function in Type 1 diabetes by mesenchymal stromal cells","volume":"64","author":"Carlsson","year":"2015","journal-title":"Diabetes"},{"key":"10.1016\/j.autrev.2021.102873_bb0120","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1136\/annrheumdis-2015-208456","article-title":"Autologous tolerogenic dendritic cells for rheumatoid and inflammatory arthritis","volume":"76","author":"Bell","year":"2017","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.autrev.2021.102873_bb0125","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1136\/annrheumdis-2015-208918","article-title":"Intravenous administration of expanded allogeneic adipose-derived mesenchymal stem cells in refractory rheumatoid arthritis (Cx611): results of a multicentre, dose escalation, randomised, single-blind, placebo-controlled phase Ib\/IIa clinical trial","volume":"76","author":"\u00c1lvaro-Gracia","year":"2017","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.autrev.2021.102873_bb0130","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1186\/s12967-018-1541-4","article-title":"Serum IFN-\u03b3 levels predict the therapeutic effect of mesenchymal stem cell transplantation in active rheumatoid arthritis","volume":"16","author":"Yang","year":"2018","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.autrev.2021.102873_bb0135","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/j.jcyt.2017.12.009","article-title":"Intra-articular knee implantation of autologous bone marrow-derived mesenchymal stromal cells in rheumatoid arthritis patients with knee involvement: results of a randomized, triple-blind, placebo-controlled phase 1\/2 clinical trial","volume":"20","author":"Shadmanfar","year":"2018","journal-title":"Cytotherapy"},{"key":"10.1016\/j.autrev.2021.102873_bb0140","doi-asserted-by":"crossref","first-page":"73","DOI":"10.5009\/gnl17035","article-title":"Umbilical cord mesenchymal stem cell treatment for Crohn\u2019s disease: a randomized controlled clinical trial","volume":"12","author":"Zhang","year":"2018","journal-title":"Gut and liver"},{"key":"10.1016\/j.autrev.2021.102873_bb0145","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0113936","article-title":"Randomized placebo-controlled phase II trial of autologous mesenchymal stem cells in multiple sclerosis","volume":"9","author":"Llufriu","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.autrev.2021.102873_bb0150","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0195891","article-title":"Adipose-derived mesenchymal stem cells (AdMSC) for the treatment of secondary-progressive multiple sclerosis: a triple blinded, placebo controlled, randomized phase I\/II safety and feasibility study","volume":"13","author":"Fern\u00e1ndez","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.autrev.2021.102873_bb0155","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1001\/jama.2012.316","article-title":"Induction therapy with autologous mesenchymal stem cells in living-related kidney transplants: a randomized controlled trial","volume":"307","author":"Tan","year":"2012","journal-title":"Jama"},{"key":"10.1016\/j.autrev.2021.102873_bb0160","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1097\/TP.0b013e3182754c53","article-title":"Donor-derived mesenchymal stem cells combined with low-dose tacrolimus prevent acute rejection after renal transplantation: a clinical pilot study","volume":"95","author":"Peng","year":"2013","journal-title":"Transplantation"},{"key":"10.1016\/j.autrev.2021.102873_bb0165","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/s12967-018-1422-x","article-title":"Allogeneic mesenchymal stem cells as induction therapy are safe and feasible in renal allografts: pilot results of a multicenter randomized controlled trial","volume":"16","author":"Sun","year":"2018","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.autrev.2021.102873_bb0170","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/j.kint.2018.08.046","article-title":"Infusion of third-party mesenchymal stromal cells after kidney transplantation: a phase I-II, open-label, clinical study","volume":"95","author":"Erpicum","year":"2019","journal-title":"Kidney Int."},{"key":"10.1016\/j.autrev.2021.102873_bb0175","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1016\/S0140-6736(20)30167-7","article-title":"Regulatory cell therapy in kidney transplantation (The ONE Study): a harmonised design and analysis of seven non-randomised, single-arm, phase 1\/2A trials","volume":"395","author":"Sawitzki","year":"2020","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.autrev.2021.102873_bb0180","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.jhep.2017.03.001","article-title":"Infusion of mesenchymal stromal cells after deceased liver transplantation: a phase I-II, open-label, clinical study","volume":"67","author":"Detry","year":"2017","journal-title":"J. Hepatol."},{"key":"10.1016\/j.autrev.2021.102873_bb0185","doi-asserted-by":"crossref","first-page":"2053","DOI":"10.1002\/sctm.17-0134","article-title":"A pilot study of mesenchymal stem cell therapy for acute liver allograft rejection","volume":"6","author":"Shi","year":"2017","journal-title":"Stem Cells Transl. Med."},{"key":"10.1016\/j.autrev.2021.102873_bb0190","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1016\/j.msard.2014.08.002","article-title":"Human placenta-derived cells (PDA-001) for the treatment of adults with multiple sclerosis: a randomized, placebo-controlled, multiple-dose study","volume":"3","author":"Lublin","year":"2014","journal-title":"Mult Scler Relat Disord"},{"key":"10.1016\/j.autrev.2021.102873_bb0195","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3006168","article-title":"Antigen-specific tolerance by autologous myelin peptide-coupled cells: a phase 1 trial in multiple sclerosis","volume":"5","author":"Lutterotti","year":"2013","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.autrev.2021.102873_bb0200","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1136\/gut.2010.215152","article-title":"Autologous bone marrow-derived mesenchymal stromal cell treatment for refractory luminal Crohn\u2019s disease: results of a phase I study","volume":"59","author":"Duijvestein","year":"2010","journal-title":"Gut"},{"key":"10.1016\/j.autrev.2021.102873_bb0205","first-page":"A295","article-title":"Pilot phase I\/II clinical trial with autologous mesenchymal stem cells in patients with multiple sclerosis and amyotrophic lateral sclerosis","volume":"74","author":"Karussis","year":"2010","journal-title":"Neurology"},{"key":"10.1016\/j.autrev.2021.102873_bb0210","doi-asserted-by":"crossref","DOI":"10.1186\/s12967-018-1541-4","article-title":"Serum IFN-gamma levels predict the therapeutic effect of mesenchymal stem cell transplantation in active rheumatoid arthritis","volume":"16","author":"Yang","year":"2018","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.autrev.2021.102873_bb0215","unstructured":"Ghoryani M, Mohammadi M, Shariati-Sarabi Z, Tavakol-Afshari J, Ghasemi A. Effect of mesenchymal stem cell therapy on TH-17 and regulatory T-cells in patients with refractory rheumatoid arthritis. Iranian journal of biotechnology 2017;Conference: 2nd national festival and international congress on stem cell and regenerative medicine. Iran, islamic republic of. 15:172\u2013173."},{"key":"10.1016\/j.autrev.2021.102873_bb0220","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1016\/j.biopha.2018.11.056","article-title":"Amelioration of clinical symptoms of patients with refractory rheumatoid arthritis following treatment with autologous bone marrow-derived mesenchymal stem cells: A successful clinical trial in Iran","volume":"109","author":"Ghoryani","year":"2019","journal-title":"Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie"},{"key":"10.1016\/j.autrev.2021.102873_bb0225","doi-asserted-by":"crossref","DOI":"10.3390\/jcm8122102","article-title":"Short and long term clinical and immunologic follow up after bone marrow mesenchymal stromal cell therapy in progressive multiple sclerosis-a phase I study","volume":"8","author":"Iacobaeus","year":"2019","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.autrev.2021.102873_bb0230","series-title":"Multiple Sclerosis Conference: 32nd Congress of the European Committee for Treatment and Research in Multiple Sclerosis","first-page":"22","article-title":"Phase II double blind trial to investigate the efficacy and the optimal way of administration (clinical, neurophysiological and neuroradiological effects) of autologous mesenchymal bone marrow stem cells in active and progressive Multiple Sclerosis","author":"Petrou","year":"2016"},{"key":"10.1016\/j.autrev.2021.102873_bb0235","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1093\/ecco-jcc\/jjv144","article-title":"Intraperitoneal Administration of Autologous Tolerogenic Dendritic Cells for refractory Crohn\u2019s disease: a phase I study","volume":"9","author":"Jauregui-Amezaga","year":"2015","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.autrev.2021.102873_bb0240","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0113936","article-title":"Randomized placebo-controlled phase II trial of autologous mesenchymal stem cells in multiple sclerosis","volume":"9","author":"Llufriu","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.autrev.2021.102873_bb0245","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1111\/cns.12559","article-title":"Impact of autologous mesenchymal stem cell infusion on Neuromyelitis Optica Spectrum disorder: a pilot, 2-year observational study","volume":"22","author":"Fu","year":"2016","journal-title":"CNS Neurosci Ther"},{"key":"10.1016\/j.autrev.2021.102873_bb0250","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1002\/sctm.18-0031","article-title":"Intravenous infusion of umbilical cord blood-derived mesenchymal stem cells in rheumatoid arthritis: a phase Ia clinical trial","volume":"7","author":"Park","year":"2018","journal-title":"Stem Cells Transl. Med."},{"key":"10.1016\/j.autrev.2021.102873_bb0255","doi-asserted-by":"crossref","first-page":"8463","DOI":"10.1073\/pnas.1820039116","article-title":"Immune tolerance in multiple sclerosis and neuromyelitis optica with peptide-loaded tolerogenic dendritic cells in a phase 1b trial","volume":"116","author":"Zubizarreta","year":"2019","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.autrev.2021.102873_bb0260","doi-asserted-by":"crossref","first-page":"2905","DOI":"10.1111\/ajt.15910","article-title":"Human leukocyte antigen selected allogeneic mesenchymal stromal cell therapy in renal transplantation: the Neptune study, a phase I single-center study","volume":"20","author":"Dreyer","year":"2020","journal-title":"Am. J. Transplant."},{"key":"10.1016\/j.autrev.2021.102873_bb0265","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1111\/ajt.15700","article-title":"Applicability, safety, and biological activity of regulatory T cell therapy in liver transplantation","volume":"20","author":"S\u00e1nchez-Fueyo","year":"2020","journal-title":"Am. J. Transplant."},{"key":"10.1016\/j.autrev.2021.102873_bb0270","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1016\/j.dld.2018.08.015","article-title":"Allogeneic mesenchymal stromal cells for refractory luminal Crohn\u2019s disease: a phase I-II study","volume":"50","author":"Gregoire","year":"2018","journal-title":"Dig. Liver Dis."},{"key":"10.1016\/j.autrev.2021.102873_bb0275","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aad4134","article-title":"Type 1 diabetes immunotherapy using polyclonal regulatory T cells","volume":"7","author":"Bluestone","year":"2015","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.autrev.2021.102873_bb0280","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1097\/MED.0b013e328355461b","article-title":"A role for tolerogenic dendritic cell-induced B-regulatory cells in type 1 diabetes mellitus","volume":"19","author":"Giannoukakis","year":"2012","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"key":"10.1016\/j.autrev.2021.102873_bb0285","first-page":"50","article-title":"Does mesenchymal stem cell therapy help multiple sclerosis patients? Report of a pilot study","volume":"4","author":"Mohyeddin Bonab","year":"2007","journal-title":"Iranian J. Immunol.\u202f: IJI"},{"key":"10.1016\/j.autrev.2021.102873_bb0290","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.jneuroim.2010.07.013","article-title":"Bone marrow mesenchymal stem cell transplantation in patients with multiple sclerosis: a pilot study","volume":"227","author":"Yamout","year":"2010","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.autrev.2021.102873_bb0295","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1111\/apt.13717","article-title":"The safety of autologous and metabolically fit bone marrow mesenchymal stromal cells in medically refractory Crohn\u2019s disease - a phase 1 trial with three doses","volume":"44","author":"Dhere","year":"2016","journal-title":"Aliment. Pharmacol. Ther."},{"key":"10.1016\/j.autrev.2021.102873_bb0300","doi-asserted-by":"crossref","first-page":"407","DOI":"10.2174\/157488812804484648","article-title":"Autologous mesenchymal stem cell therapy in progressive multiple sclerosis: an open label study","volume":"7","author":"Bonab","year":"2012","journal-title":"Curr Stem Cell Res Ther"},{"key":"10.1016\/j.autrev.2021.102873_bb0305","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1001\/archneurol.2010.248","article-title":"Safety and immunological effects of mesenchymal stem cell transplantation in patients with multiple sclerosis and amyotrophic lateral sclerosis","volume":"67","author":"Karussis","year":"2010","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.autrev.2021.102873_bb0310","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1111\/cns.12759","article-title":"Mesenchymal stem cells and conditioned media in the treatment of multiple sclerosis patients: clinical, ophthalmological and radiological assessments of safety and efficacy","volume":"23","author":"Dahbour","year":"2017","journal-title":"CNS Neurosci Ther"},{"key":"10.1016\/j.autrev.2021.102873_bb0315","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1177\/1352458517703802","article-title":"Pilot trial of intravenous autologous culture-expanded mesenchymal stem cell transplantation in multiple sclerosis","volume":"24","author":"Cohen","year":"2018","journal-title":"Multiple sclerosis (Houndmills, Basingstoke, England)"},{"key":"10.1016\/j.autrev.2021.102873_bb0320","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/s12967-018-1433-7","article-title":"Clinical feasibility of umbilical cord tissue-derived mesenchymal stem cells in the treatment of multiple sclerosis","volume":"16","author":"Riordan","year":"2018","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.autrev.2021.102873_bb0325","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.cgh.2013.06.021","article-title":"A phase 2 study of allogeneic mesenchymal stromal cells for luminal Crohn\u2019s disease refractory to biologic therapy","volume":"12","author":"Forbes","year":"2014","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"10.1016\/j.autrev.2021.102873_bb0330","first-page":"71","article-title":"Multiple injections with autologous mesenchymal stem cells (MSC) in patients with progressive forms of multiple sclerosis: a long term open trial","volume":"22","author":"Petrou","year":"2016","journal-title":"Mult. Scler. J."},{"key":"10.1016\/j.autrev.2021.102873_bb0335","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1002\/sctm.17-0198","article-title":"Feasibility, safety, and tolerance of mesenchymal stem cell therapy for obstructive chronic lung allograft dysfunction","volume":"7","author":"Keller","year":"2018","journal-title":"Stem Cells Transl. Med."},{"key":"10.1016\/j.autrev.2021.102873_bb0340","doi-asserted-by":"crossref","first-page":"4331","DOI":"10.2147\/DDDT.S225613","article-title":"Efficacy and safety of umbilical cord mesenchymal stem cell therapy for rheumatoid arthritis patients: a prospective phase I\/II study","volume":"13","author":"Wang","year":"2019","journal-title":"Drug Design Development and Therapy"},{"key":"10.1016\/j.autrev.2021.102873_bb0345","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/S1474-4422(11)70305-2","article-title":"Autologous mesenchymal stem cells for the treatment of secondary progressive multiple sclerosis: an open-label phase 2a proof-of-concept study","volume":"11","author":"Connick","year":"2012","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.autrev.2021.102873_bb0350","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1136\/annrheumdis-2015-208918","article-title":"Intravenous administration of expanded allogeneic adipose-derived mesenchymal stem cells in refractory rheumatoid arthritis (Cx611): results of a multicentre, dose escalation, randomised, single-blind, placebo-controlled phase Ib\/IIa clinical trial","volume":"76","author":"Alvaro-Gracia","year":"2017","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.autrev.2021.102873_bb0355","doi-asserted-by":"crossref","first-page":"107","DOI":"10.5966\/sctm.2012-0114","article-title":"Autologous bone marrow-derived mesenchymal stromal cells for the treatment of allograft rejection after renal transplantation: results of a phase I study","volume":"2","author":"Reinders","year":"2013","journal-title":"Stem Cells Transl. Med."},{"key":"10.1016\/j.autrev.2021.102873_bb0360","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1001\/archneurol.2010.248","article-title":"Safety and immunological effects of mesenchymal stem cell transplantation in patients with multiple sclerosis and amyotrophic lateral sclerosis","volume":"67","author":"Karussis","year":"2010","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.autrev.2021.102873_bb0365","first-page":"650","article-title":"Pilot phase I\/II clinical trial with autologous mesenchymal stem cells in patients with multiple sclerosis and amyotrophic lateral sclerosis","volume":"21","author":"Karussis","year":"2010","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.autrev.2021.102873_bb0370","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1053\/j.gastro.2012.07.116","article-title":"Safety and efficacy of antigen-specific regulatory T-cell therapy for patients with refractory Crohn\u2019s disease","volume":"143","author":"Desreumaux","year":"2012","journal-title":"Gastroenterology"},{"key":"10.1016\/j.autrev.2021.102873_bb0375","doi-asserted-by":"crossref","first-page":"2945","DOI":"10.1111\/ajt.14415","article-title":"Polyclonal regulatory T cell therapy for control of inflammation in kidney transplants","volume":"17","author":"Chandran","year":"2017","journal-title":"Am. J. Transplant."},{"key":"10.1016\/j.autrev.2021.102873_bb0380","series-title":"A Phase I Clinical Trial with Ex Vivo Expanded Recipient Regulatory T cells in Living Donor Kidney Transplants Scientific reports","first-page":"7428","volume":"8","author":"Mathew","year":"2018"},{"key":"10.1016\/j.autrev.2021.102873_bb0385","series-title":"Growing evidence supporting the use of mesenchymal stem cell therapies in multiple sclerosis: A systematic review Multiple sclerosis and related disorders","first-page":"101860","volume":"38","author":"Oliveira","year":"2020"},{"key":"10.1016\/j.autrev.2021.102873_bb0390","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1007\/s12015-020-09954-z","article-title":"Therapeutic potential of mesenchymal stromal stem cells in rheumatoid arthritis: a systematic review of in vivo studies","volume":"16","author":"Karamini","year":"2020","journal-title":"Stem Cell Rev. Rep."},{"key":"10.1016\/j.autrev.2021.102873_bb0395","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1007\/s10151-019-02024-8","article-title":"Mesenchymal stem-cell therapy for perianal fistulas in Crohn\u2019s disease: a systematic review and meta-analysis","volume":"23","author":"Cheng","year":"2019","journal-title":"Tech Coloproctol"},{"key":"10.1016\/j.autrev.2021.102873_bb0400","doi-asserted-by":"crossref","first-page":"8536785","DOI":"10.1155\/2019\/8536785","article-title":"Autologous mesenchymal stem cell transplantation in multiple sclerosis: a meta-analysis","volume":"2019","author":"Zhou","year":"2019","journal-title":"Stem Cells Int."},{"key":"10.1016\/j.autrev.2021.102873_bb0405","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0047559","article-title":"Safety of cell therapy with mesenchymal stromal cells (SafeCell): a systematic review and meta-analysis of clinical trials","volume":"7","author":"Lalu","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.autrev.2021.102873_bb0410","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2019-030309","article-title":"Tolerogenic dendritic cell-based treatment for multiple sclerosis (MS): a harmonised study protocol for two phase I clinical trials comparing intradermal and intranodal cell administration","volume":"9","author":"Willekens","year":"2019","journal-title":"BMJ Open"},{"key":"10.1016\/j.autrev.2021.102873_bb0415","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1016\/S0140-6736(16)31203-X","article-title":"Expanded allogeneic adipose-derived mesenchymal stem cells (Cx601) for complex perianal fistulas in Crohn\u2019s disease: a phase 3 randomised, double-blind controlled trial","volume":"388","author":"Pan\u00e9s","year":"2016","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.autrev.2021.102873_bb0420","doi-asserted-by":"crossref","first-page":"112907","DOI":"10.1016\/j.jim.2020.112907","article-title":"Guidelines for analysis of low-frequency antigen-specific T cell results: dye-based proliferation assay vs 3H-thymidine incorporation","volume":"487","author":"Di Blasi","year":"2020","journal-title":"J. Immunol. Methods"},{"key":"10.1016\/j.autrev.2021.102873_bb0425","first-page":"27","article-title":"MEsenchymal StEm cells for Multiple Sclerosis (MESEMS) study: results from a multi-center, randomized, double blind, cross-over phase 2 clinical trial with autologous Mesenchymal Stem Cells (MSC) for the therapy of multiple sclerosis","volume":"27","author":"Uccelli","year":"2020","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.autrev.2021.102873_bb0430","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaa7721","article-title":"Hurdles in therapy with regulatory T cells","volume":"7","author":"Trzonkowski","year":"2015","journal-title":"Sci. Transl. Med."}],"container-title":["Autoimmunity Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997221001464?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997221001464?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T21:21:28Z","timestamp":1761600088000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1568997221001464"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8]]},"references-count":86,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2021,8]]}},"alternative-id":["S1568997221001464"],"URL":"https:\/\/doi.org\/10.1016\/j.autrev.2021.102873","relation":{},"ISSN":["1568-9972"],"issn-type":[{"value":"1568-9972","type":"print"}],"subject":[],"published":{"date-parts":[[2021,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety and immunological proof-of-concept following treatment with tolerance-inducing cell products in patients with autoimmune diseases or receiving organ transplantation: A systematic review and meta-analysis of clinical trials","name":"articletitle","label":"Article Title"},{"value":"Autoimmunity Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.autrev.2021.102873","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"102873"}}